Monthly funding roundup across health, longevity, healthcare AI, diagnostics, nutrition and consumer health, highlighting key deals and emerging signals.
Key Takeaways
- Alan now serves approximately one million European members and will use funding to expand
- NewLimit develops epigenetic reprogramming therapies and targets alcohol-related liver disease first
- TruNativ raised a $30 million Series B led by OrbiMed to expand nutrition products